Godavari Biorefineries Expands to US with New Subsidiary
Filing Summary
Godavari Biorefineries Limited has announced the establishment of Sathgen Therapeutics LLC, a wholly owned subsidiary based in Princeton, New Jersey. This expansion aims to enhance the company’s biotechnology presence in the United States. Dr. Padmaja Ganpathy will serve as CEO, and Dr. Sendurai Mani as Chief Scientific Officer. The subsidiary will focus on global out-licensing of intellectual property and advancing drug development programs. Sathgen Therapeutics has secured patents in the US, Europe, and China, and has formed a Scientific Advisory Board to guide its clinical development strategy.
Godavari Biorefineries Limited (GBL) has announced the incorporation of Sathgen Therapeutics LLC, a wholly owned subsidiary located in Princeton, New Jersey, USA. This development is part of GBL’s strategy to expand its clinical-stage biotechnology presence in the United States. The new subsidiary will focus on the global out-licensing of intellectual property and building a network to accelerate drug development programs.
The filing does not specify any financial terms or payment structures related to the establishment of the subsidiary. The focus is on expanding GBL’s operational capabilities in the biotechnology sector, particularly in the United States.
Sathgen Therapeutics originated from an idea proposed by Dr. Sendurai Mani, supported by Mr. Samir Somaiya, Chairman and Managing Director of GBL. The program is focused on discovering and developing novel molecules, with several candidates showing preclinical efficacy in triple-negative breast cancer (TNBC) and other cancers. Sathgen has secured patents in the US, Europe, China, and other key markets. The subsidiary will engage in collaborations to advance its discoveries and ensure they reach patients.
The establishment of the US subsidiary marks a significant step in GBL’s efforts to translate scientific research into practical solutions. The company has formed a Scientific Advisory Board to guide its clinical development and translational research strategy. The board includes experts such as Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli, who will contribute their expertise in oncology and clinical-trial design.
Dr. Padmaja Ganpathy will take over as CEO of Sathgen Therapeutics USA, and Dr. Sendurai Mani will serve as Chief Scientific Officer. The subsidiary aims to deepen collaborations with global scientific and clinical partners. The filing does not provide specific implementation dates or milestones for the subsidiary’s operations.
Godavari Biorefineries Limited is a leading integrated biorefinery specializing in bio-based chemicals, ethanol, and sugar & power production. The company is a major producer of ethanol and a pioneer in manufacturing ethanol-based chemicals in India. GBL operates advanced facilities in Maharashtra and Karnataka and is committed to sustainability and innovation in renewable energy and green chemistry.